What is Specialty Pharmacy? A Video from Avella

The gap is not a paperwork inconvenience—it is a cash flow problem with clinical consequences.

Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.

FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.

Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.

Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.

A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.

In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.

A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.